Rhythm Pharmaceuticals
RYTM
303 hedge funds and large institutions have $8.55B invested in Rhythm Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 105 increasing their positions, 101 reducing their positions, and 41 closing their positions.
56% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 41
53% more call options, than puts
Call options by funds: $17.6M | Put options by funds: $11.5M
33% more capital invested
Capital invested by funds: $6.42B → $8.55B (+$2.13B)
6% more funds holding
Funds holding: 285 → 303 (+18)
4.94% more ownership
Funds ownership: 107.74% → 112.69% (+4.9%)
4% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 101
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$99.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$82.4M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$45.2M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$37.7M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$37.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$60M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$39.1M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$30.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$29.7M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$29.4M |
RYTM Hedge Fund Activity: Q2 2026 in Review
303 institutional investors reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2026, worth a combined $8.55B — up 33% from $6.42B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new RYTM positions and 41 closed out — a net gain of 23 holders — while 105 added to existing stakes and 101 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $99.4M. The largest seller was Fidelity Investments, cutting an estimated $60M.
- 303 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2026, up from 285 in Q1 2026.
- Funds reported $8.55B of Rhythm Pharmaceuticals stock for Q2 2026, up 33% quarter-over-quarter.
- 64 funds opened new Rhythm Pharmaceuticals positions in Q2 2026 and 41 closed out, a net change of +23 holders.
- The largest Rhythm Pharmaceuticals buyer in Q2 2026 was JP Morgan Chase, an estimated $99.4M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2026 was Fidelity Investments, an estimated $60M sold.
Based on aggregated 13F filings for Q2 2026.